Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for SC Ropharma's EV-to-EBIT or its related term are showing as below:
BSE:RPH's EV-to-EBIT is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 15.56 * Ranked among companies with meaningful EV-to-EBIT only.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
SC Ropharma's Enterprise Value for the quarter that ended in Dec. 2024 was lei239 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. SC Ropharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was lei27 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SC Ropharma EV-to-EBIT Related Terms
SC Ropharma EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for SC Ropharma's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, SC Ropharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SC Ropharma EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, SC Ropharma's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where SC Ropharma's EV-to-EBIT falls into.
SC Ropharma's current Enterprise Value is lei255 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. SC Ropharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was lei27 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SC Ropharma (BSE:RPH) has a EV-to-EBIT of 9.30 as of Sep. 06, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on SC Ropharma and its competitors.
Is SC Ropharma's EV-to-EBIT too high?
SC Ropharma's current EV-to-EBIT is 9.30. The Healthcare Providers & Services industry median EV-to-EBIT is 15.56. SC Ropharma's value of 9.30 is 40.2% below this industry median. Overall, SC Ropharma has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does SC Ropharma's EV-to-EBIT compare to competitors?
SC Ropharma's EV-to-EBIT of 9.30 can be compared against companies in the Healthcare Providers & Services industry. The industry median EV-to-EBIT is 15.56. SC Ropharma's value of 9.30 is 40.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Healthcare Providers & Services company?
The median EV-to-EBIT among Healthcare Providers & Services companies is 15.56, based on 474 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SC Ropharma's current EV-to-EBIT of 9.30 is 40.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on SC Ropharma and its competitors. For the Healthcare Providers & Services industry, the median EV-to-EBIT is 15.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SC Ropharma's current EV-to-EBIT is 9.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SC Ropharma stock overvalued right now?
SC Ropharma (BSE:RPH) has a current EV-to-EBIT of 9.30. The current EV-to-EBIT is 9.30 and 40.2% below the Healthcare Providers & Services industry median of 15.56. SC Ropharma's overall GF Score™ is 66/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For SC Ropharma (BSE:RPH), the current EV-to-EBIT is 9.30 as of Sep. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SC Ropharma SA is engaged in the production, distribution, and Retail sale of pharmaceutical products in specialized stores. Its product portfolio comprises over 50 products in the form of tablets, powders, capsules, and syrups covering 21 therapeutic areas.
66GF Score
Get the complete analysis for BSE:RPH
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSE:RPH has been successfully added to your 
